

Genfore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 15, 2003, 15:34:17 Search for 52,386 Sequences
(without alignments)
28,011 Million cell updates/sec

Title: us-09-856-070-23

Perfect score: 55

Sequence: 1 ELMRLQRYEE 11

Scoring table: BLOSUM62

Gapop 10.0, Gap-xt 0.5

Searched: 908470 seqs, 13350620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A_Geneseq_101002.*

1:	/SID22/qcdata/qcseq/geneseq-emb1/AA1980.DAT.*
2:	/SID22/qcdata/qcseq/geneseq-emb1/AA1981.DAT.*
3:	/SID22/qcdata/qcseq/geneseq-emb1/AA1982.DAT.*
4:	/SID22/qcdata/qcseq/geneseq-emb1/AA1983.DAT.*
5:	/SID22/qcdata/qcseq/geneseq-emb1/AA1984.DAT.*
6:	/SID22/qcdata/qcseq/geneseq-emb1/AA1985.DAT.*
7:	/SID22/qcdata/qcseq/geneseq-emb1/AA1986.DAT.*
8:	/SID22/qcdata/qcseq/geneseq-emb1/AA1987.DAT.*
9:	/SID22/qcdata/qcseq/geneseq-emb1/AA1988.DAT.*
10:	/SID22/qcdata/qcseq/geneseq-emb1/AA1989.DAT.*
11:	/SID22/qcdata/qcseq/geneseq-emb1/AA1990.DAT.*
12:	/SID22/qcdata/qcseq/geneseq-emb1/AA1991.DAT.*
13:	/SID22/qcdata/qcseq/geneseq-emb1/AA1992.DAT.*
14:	/SID22/qcdata/qcseq/geneseq-emb1/AA1993.DAT.*
15:	/SID22/qcdata/qcseq/geneseq-emb1/AA1994.DAT.*
16:	/SID22/qcdata/qcseq/geneseq-emb1/AA1995.DAT.*
17:	/SID22/qcdata/qcseq/geneseq-emb1/AA1996.DAT.*
18:	/SID22/qcdata/qcseq/geneseq-emb1/AA1997.DAT.*
19:	/SID22/qcdata/qcseq/geneseq-emb1/AA1998.DAT.*
20:	/SID22/qcdata/qcseq/geneseq-emb1/AA1999.DAT.*
21:	/SID22/qcdata/qcseq/geneseq-emb1/AA2000.DAT.*
22:	/SID22/qcdata/qcseq/geneseq-emb1/AA2001.DAT.*
23:	/SID22/qcdata/qcseq/geneseq-emb1/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	55	100.0	11	AA882039	Human heprecceptor
2	55	100.0	12	AA882038	Human heprecceptor
3	55	100.0	13	AA882037	Human heprecceptor
4	55	100.0	34	AA882036	Human heprecceptor
5	55	100.0	436	AA882035	Human colon cancer
6	55	100.0	546	AA882034	Amino acid sequence
7	55	100.0	622	AA882033	Novel human secret
8	55	100.0	635	AA882032	Human colon cancer
9	47	85.5	52	AA882031	Novel human secret
10	41	74.5	27	AA882030	Asienrapedia inter

11	40	72.7	344	22	APG29165	Novel human diapo
12	39	70.9	57	22	AB336680	Peptide #7186 enco
13	39	70.9	57	22	AA66396	Human brain expres
14	39	70.9	57	22	AA673032	Human bone marrow
15	39	70.9	57	22	AA633256	Peptide #7293 enco
16	39	70.9	57	23	AB42876	Human peptide enco
17	39	70.9	429	22	AB19048	Novel human diapo
18	39	70.9	429	22	AA74841	Human colon cancer
19	39	70.9	802	22	AB19045	Novel human diapo
20	39	70.9	2645	22	AB220077	Novel human diapo
21	37	67.3	21	23	AB289657	Insulin/insulin-li
22	36	65.5	284	21	AA630197	Arabidopsis thalia
23	36	65.5	284	21	AA630196	Arabidopsis thalia
24	36	65.5	293	21	AA630196	Arabidopsis thalia
25	36	65.5	293	21	AA630196	Arabidopsis thalia
26	36	65.5	1200	21	AA630196	Arabidopsis thalia
27	35	63.6	444	22	AB68491	Amino acid sequenc
28	35	63.6	892	22	AB68491	Proscophila melanog
29	34	61.8	176	21	AA630197	Alpha-actinin prot
30	34	61.8	176	21	AA630197	Arabidopsis thalia
31	34	61.8	186	21	AA630197	Arabidopsis thalia
32	34	61.8	186	21	AA630197	Arabidopsis thalia
33	34	61.8	186	21	AA630197	Arabidopsis thalia
34	34	61.8	289	21	AA630197	Arabidopsis thalia
35	34	61.8	333	21	AA630197	Arabidopsis thalia
36	34	61.8	333	21	AA630197	Arabidopsis thalia
37	34	61.8	333	21	AA630197	Arabidopsis thalia
38	34	61.8	333	22	AB88669	Rice Photosensitiv
39	34	61.8	333	23	AA630197	Meta vulgaris case
40	34	61.8	333	23	AA630197	Physcomitrella pat
41	34	61.8	405	11	AA630197	CDX, a MILA involy
42	34	61.8	405	12	AA630197	GDP Fuc-beta-D-Gal
43	34	61.8	405	12	AA630197	Protein 7.2 (1.3-f
44	34	61.8	405	13	AA630197	beta cell facosylt
45	34	61.8	405	15	AA630197	A glycosyltransfer

ALIGNMENTS

RESU(T 1	
AA882039	
10	AA882039 standard, peptide; 11 AA.
XX	
AC	AA882039:
XX	
ET	13-JUN 2001 (first entry)
DE	Human heprecceptor domain A binding peptide Rupe2232.
XX	
AW	Human heprecceptor, cytostatic, anti-HIV; antibiotic;
KW	Neutrophil, immune response inducer, anti-HIV; infectious
KW	HIV-related dementia.
XX	
OS	Homo sapiens.
XX	
FT	Key location/qualifiers
FT	Modified-site 9
FT	/note- "Optionally phosphorylated"
XX	
FN	GB2354241-A.
XX	
PD	21-MAR-2001.
XX	
FF	17 SEP 1999. 99GB 0021881.
XX	
FE	17 SEP 1999. 99GB 0021881.
XX	
FA	(HOLM/) HOLMS R D.
XX	
PI	Holms RD;
XX	
DR	WFI: 2001 293287/31.

XX Novel regulatory or unfolding peptides of ezrin that binds to
 PT heprecceptor, useful for inducing immune response for treating
 PT infectious diseases and cancer

PS Claim 26; Page 37; 42pp; English.

XX The heprecceptor is a novel active site in human ezrin. Ezrin regulates
 CC the structure of the cortical cytoskeleton to control cell surface
 CC topography. The present invention relates to peptides (see AAB82021 to
 CC AAB82041) that bind to heprecceptor with greater affinity than HEPI (see
 CC AAB82046). The heprecceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and
 CC HIV-related dementia. The present peptide binds to domain A of the
 CC heprecceptor (AAB82019).

XX Sequence 11 AA;

Query Match 100.0%; Score 55; DB 22; Length 11;
 Best local Similarity 100.0%; Pred. No. 0.0043;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11

DB 1 ELMRLQDYEE 11

RESULT 2

AAB82038
 ID AAB82038 standard; peptide; 12 AA.

XX AAB82038;

XX 13-JUN-2001 (first entry)

DE Human heprecceptor domain A binding peptide Rupe2132.

XX Human; heprecceptor; cytostatic; anti-HIV; antibiotic;
 KW neotropic; immune response inducer; ezrin; infectious diseases; cancer.
 KW HIV related dementia.

XX Homo sapiens.

XX Key Location/Qualifiers
 FT Modified-site 10
 FT /note- "Optionally phosphorylated"

XX GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001-293287/41.

XX Novel regulatory or unfolding peptides of ezrin that binds to
 PT heprecceptor, useful for inducing immune response for treating
 PT infectious diseases and cancer

PS Claim 24; Page 46; 42pp; English.

XX The heprecceptor is a novel active site in human ezrin. Ezrin regulates
 CC the structure of the cortical cytoskeleton to control cell surface
 CC topography. The present invention relates to peptides (see AAB82021 to
 CC AAB82041) that bind to heprecceptor with greater affinity than HEPI (see
 CC AAB82046). The heprecceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and

CC HIV related dementia. The present peptide binds to domain A of the
 CC heprecceptor (AAB82019).

XX Sequence 12 AA;

Query Match 100.0%; Score 55; DB 22; Length 12;
 Best local Similarity 100.0%; Pred. No. 0.0047;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11

DB 2 ELMRLQDYEE 12

RESULT 3

AAB82047
 ID AAB82037 standard; peptide; 13 AA.

XX AAB82037;

XX 13-JUN-2001 (first entry)

DE Human heprecceptor domain A binding peptide Rupe2032.

XX Human; heprecceptor; cytostatic; anti-HIV; antibiotic;
 KW neotropic; immune response inducer; ezrin; infectious diseases; cancer.
 KW HIV-related dementia.

XX Homo sapiens.

XX Key Location/Qualifiers
 FT Modified-site 11
 FT /note- "Optionally phosphorylated"

XX GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001-293287/41.

XX Novel regulatory or unfolding peptides of ezrin that binds to
 PT heprecceptor, useful for inducing immune response for treating
 PT infectious diseases and cancer

PS Claim 22; Page 36; 42pp; English.

XX The heprecceptor is a novel active site in human ezrin. Ezrin regulates
 CC the structure of the cortical cytoskeleton to control cell surface
 CC topography. The present invention relates to peptides (see AAB82021 to
 CC AAB82041) that bind to heprecceptor with greater affinity than HEPI (see
 CC AAB82046). The heprecceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and
 CC HIV related dementia. The present peptide binds to domain A of the
 CC heprecceptor (AAB82019).

XX Sequence 13 AA;

Query Match 100.0%; Score 55; DB 22; Length 13;
 Best local Similarity 100.0%; Pred. No. 0.0051;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11

DB 3 ELMRLQDYEE 13

RESULT 4
 AAB82020
 ID AAB82020 standard; peptide: 34 AA.
 XX
 AC AAB82020;
 DT 13-JUN-2001 (first entry)
 DE Human hepreceptor domain B.
 KW Human: hepreceptor domain B, cytostatic; anti-HIV; antibiotic;
 KW neotrophic, immune response inducer, ezrin, infectious diseases, cancer;
 KW HIV-related dementia.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FI Modified-site 14 /note- "Optionally phosphorylated"
 XX GR2454241-A.
 XX 21-MAR-2001.
 PF 17-SEP-1999; 99GR-0021881.
 PR 17-SEP-1999; 99GR-0021881.
 PA (HOLM/) HOLMS R D.
 PI Holms RD;
 XX WPI: 2001 293287/31
 XX Novel regulatory or un-folding peptides of ezrin that binds to
 PT hepreceptor, useful for inducing immune response for treating
 PT infectious diseases and cancer.
 XX Claim 5; Page 36; 42pp; English.
 CC The present sequence is domain B of human hepreceptor of human ezrin. The
 CC hepreceptor is a novel active site in human ezrin. Ezrin regulates the
 CC structure of the cortical cytoskeleton to control cell surface
 CC topography. The present invention relates to peptides (see AAB82021 to
 CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
 CC AAB82046). The hepreceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and
 CC HIV-related dementia. The present sequence assembles into two
 CC anti-parallel helices with hepreceptor domain A (see AAB82017).
 SQ Sequence 34 AA;
 Query Match 100.0%; Score 55; DB 22; Length 34;
 Best Local Similarity 100.0%; Prod. No. 0.914;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ELMRLQDYEE 11
 DB 6 ELMRLQDYEE 16
 RESULT 5
 AAG73954
 ID AAG73954 standard; Protein: 436 AA.
 XX
 AC AAG73954;
 DT 03-SEP-2001 (first entry)
 DE Human colon cancer antigen protein SEQ ID NO:4718.
 XX Human: colon cancer; colon cancer antigen; diagnosis; detection;

colorectal carcinoma.
 XX Homo sapiens.
 PN WO200122920-A2.
 XX 05-APR-2001.
 XX 28-SEP-2000; 2000WO-0526524.
 PF 29-SEP-1999; 99US-0157137.
 PR 03-NOV-1999; 99US-0163280.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Ruben SM, Barash SC, Birse CE, Rosen CA;
 DE WPI: 2001 235357/24.
 DR N-PSDH; AAB33385.
 XX Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
 PT useful for preventing, diagnosing and/or treating colorectal cancers -
 XX Claim 11; Page 6520-6521; 9803pp; English.
 XX AAB32943 to AAB37195 and AAG73514 to AAG77788 represent human colon
 CC cancer-associated nucleic acid molecules (N) and proteins (P), where
 CC the proteins are collectively known as colon cancer antigens. The colon
 CC cancer antigens have cytostatic activity and can be used in gene
 CC therapy and vaccine production. N and P may be used in the prevention,
 CC diagnosis and treatment of diseases associated with inappropriate P
 CC expression. For example, N and P may be used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of P by expressing of P
 CC inactive proteins or to supplement the patient's own production of P.
 CC Additionally, N may be used to produce the colon cancer-associated ps,
 CC by inserting the nucleic acids into a host cell and culturing the cell
 CC to express the proteins. N and P can be used in the prevention, diagnosis
 CC and treatment of colorectal carcinomas and cancers. AAB37196 to AAB37204
 CC and AAB77789 represent sequences used in the exemplification of the
 CC present invention.
 CC N.B. Gaps 00 to 682 and page 7153 of the sequence listing were
 CC missing at time of publication, meaning no sequences are present for
 CC SEQ ID NO:1627 to 1652, 7921 and 7922.
 XX SQ Sequence 436 AA;
 Query Match 100.0%; Score 55; DB 22; Length 436;
 Best Local Similarity 100.0%; Prod. No. 0.18;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ELMRLQDYEE 11
 DB 196 ELMRLQDYEE 206
 RESULT 6
 AAY27443
 ID AAY27443 standard; protein: 586 AA.
 XX
 AC AAY27443;
 XX 26-NOV-1999 (first entry)
 DE Amino acid sequence of human ezrin polypeptide.
 XX Pharmaceutical; ezrin; mutant; tumor; metastasis; human.
 KW Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FI Misc-difference 354 /note- "the tyr at this position can be mutated
 FI

PT (preferably to a pHe) to construct an
 PT ezrin mutant of the invention".
 XX
 XX W09947150-A2.
 XX
 XX 23-SEP-1999.
 XX
 XX 18-MAR-1999; 99WO-EP02054.
 XX
 XX 18-MAR-1998; 98US-0040725.
 XX
 XX (CDRI-) INST CURIE.
 XX (CNRS) CNRS CENT NAT RECH SCI.
 XX
 XX Arpin M, Crepaldi L, Gauthier A, Louvard D;
 XX WPI; 1999-561851/47.
 XX
 XX New composition for prevention and treatment of tumors and metastasis
 PT
 PT
 XX Example 1; Fig 1; 31pp; English.
 XX
 XX The invention provides a pharmaceutical composition containing ezrin
 CC protein, RNA or DNA mutated on tyrosine 553, or a functional fragment
 CC or derivative of the ezrin mutant. The new composition is useful for
 CC prevention and/or treatment of tumors, and especially metastasis. The
 CC present sequence represents the amino acid sequence of human ezrin
 CC (before the maturation by deletion of the first amino acid Met).
 XX
 XX Sequence 586 AA;
 SQ
 Query Match 100.0%; Score 55; DB 20; Length 586;
 Best Local Similarity 100.0%; Pred. No. 0.25;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ELMRLQDYEE 11
 IIIIIIIIII
 DB 346 ELMRLQDYEE 456
 RESULT 7
 AAU30004
 ID AAU30004 standard; Protein; 622 AA.
 AC AAU30004;
 XX
 XX 18-DEC-2001 (first entry)
 XX
 XX Novel human secreted protein #495.
 XX
 XX Human; vaccination; gene therapy; nutritional supplement;
 KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
 KW
 XX Homo sapiens.
 OS
 XX W020017449 A2.
 XX
 XX 25 OCT 2001.
 XX
 XX 16-APR-2001; 2001WO-0508056.
 XX
 XX 18-APR-2000; 2000US-0552929.
 XX 26-JAN-2001; 2001US-0770160.
 XX
 XX (HYSE-) HYSEQ INC.
 XX
 XX Tang YL, Liu C, Brmanac RJ;
 XX WPI; 2001-611725/76.
 XX
 XX Nucleic acids encoding a range of human polypeptides, useful in genetic

PT vaccination, testing and therapy -
 XX
 XX Claim 20; Page 219, 765pp; English.
 XX
 XX The invention relates to novel human secreted polypeptides. The
 CC polypeptides and antibodies to the polypeptides are useful for
 CC determining the presence of or predisposition to a disease associated
 CC with altered levels of polypeptide. The polypeptides are also useful for
 CC identifying agents (agonists and antagonists) that bind to them. Cells
 CC expressing the proteins are useful for identifying a therapeutic agent
 CC for use in treatment of a pathology related to aberrant expression or
 CC physical interactions of the polypeptide. Vectors comprising
 CC the nucleic acids encoding the polypeptides and cells genetically
 CC engineered to express them are also useful for producing the proteins.
 CC The proteins are useful in genetic vaccination, testing and
 CC therapy, and can be used as nutritional supplements. They may be used to
 CC increase stem cell proliferation; to regulate haematopoiesis; and in
 CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
 CC immune suppression and/or stimulation; as anti-inflammatory agents; and
 CC in treatment of leukaemias. AAU29510-AAU33404 represent the amino acid
 CC sequences of novel human secreted proteins of the invention.
 XX
 XX Sequence 622 AA;
 SQ
 Query Match 100.0%; Score 55; DB 22; Length 622;
 Best Local Similarity 100.0%; Pred. No. 0.26;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ELMRLQDYEE 11
 IIIIIIIIII
 DB 382 ELMRLQDYEE 392
 RESULT 8
 AAB53356
 ID AAB53356 standard; Protein; 635 AA.
 AC AAB53356;
 XX
 XX 09-MAR-2001 (first entry)
 XX
 XX Human colon cancer antigen protein sequence SEQ ID No:896.
 XX
 XX Human; colon cancer; colon cancer antigen; diagnosis; detection;
 KW identification; cytostatic; cardioactive; neuroprotective; vulnery;
 KW immunomodulatory; muscular; gynaecological; gastrointestinal;
 KW nephrotropic; antineoplastic; antibacterial; gene therapy; wound;
 KW neural disorder; immune system disorder; muscular disorder;
 KW reproductive disorder; gastrointestinal disorder; renal disorder;
 KW infectious disease; cardiovascular disorder.
 XX
 XX Homo sapiens.
 OS
 XX WO200055351-A1.
 XX
 XX 21-SEP-2000.
 XX
 XX 08-MAR-2000; 2000WO-0505883.
 XX
 XX 12-MAR-1999; 99US-0124270.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Rosen CA, Ruben SM;
 XX WPI; 2000-587534/55.
 XX N-PSDB; AAC98113.
 XX
 XX Colon cancer associated gene sequences, referred to as colon cancer
 PT antigens, useful for the treatment, prevention, and diagnosis of colon
 PT disorders such as colon cancer -
 XX
 XX Claim 11; Page 1449-1451; 2104pp; English.

XX AAC97991 to AAC98763 encode the human colon cancer associated proteins,
 CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
 CC human colon cancer antigens can have cytostatic, cardioactive, muscular,
 CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal, and
 CC vulvar, nephrologic, antineoplastic and antibacterial activities, and
 CC can be used in gene therapy. The colon cancer antigen polynucleotides,
 CC proteins and antibodies to the proteins are useful for the prevention,
 CC treatment and diagnosis of colon disorders, such as colon cancer. The
 CC polynucleotides may be used in diagnostics and research, such as for
 CC chromosome identification, and as hybridisation probes. The proteins
 CC may also be used to prevent diseases such as neural disorders, immune
 CC system disorders, muscular disorders, reproductive disorders,
 CC gastrointestinal disorders, wounds, renal disorders, infections
 CC diseases, and cardiovascular disorders. AA-58764 to AA-58772 and
 CC AAB54007 represent sequences used in the exemplification of the present
 CC invention.
 XX
 SQ Sequence 635 AA;
 Query Match 100.0%; Score 55; DB 21; Length 645;
 Best Local Similarity 100.0%; Pred No. 0.27;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ELMRLQDYEE 11
 Db 395 ELMRLQDYEE 405
 PPSU 9
 AA033060
 ID AA033060 standard; Protein: 52 AA.
 AC AA033060;
 XX
 DI 18-DEC-2001 (first entry)
 XX
 DE Novel human secreted protein #3551.
 XX
 KW Human; vaccination; gene therapy; nutritional supplement;
 KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
 XX
 OS Homo sapiens.
 XX
 PN WO200179449-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 16-APR-2001; 2001WO-0508656.
 XX
 PP 18-APR-2000; 2000US-0552924.
 PP 26-JAN-2001; 2001US-0770160.
 XX
 PA (HYSK-) HYSEQ INC.
 XX
 PI Tang YI, Liu C, Dermanac ET;
 XX
 DR WPI: 2001-611725/70.
 XX
 PI Nucleic acids encoding a range of human polypeptides, useful in genetic
 PT vaccination, testing and therapy.
 PT
 PS Claim 20, Page 762, 765pp, English.
 XX
 CC The invention relates to novel human secreted polypeptides. The
 CC polypeptides and antibodies to the polypeptides are useful for
 CC determining the presence of or predisposition to a disease associated
 CC with altered levels of polypeptide. The polypeptides are also useful for
 CC identifying agents (agonists and antagonists) that bind to them. Cells
 CC expressing the proteins are useful for identifying a therapeutic agent
 CC for use in treatment of a pathology related to aberrant expression or
 CC physiological interactions of the polypeptide. Vectors comprising

CC the nucleic acids encoding the polypeptides and cells genetically
 CC engineered to express them are also useful for producing the proteins.
 CC The proteins are useful in genetic vaccination, testing and
 CC therapy, and can be used as nutritional supplements. They may be used to
 CC increase stem cell proliferation, to regulate haematopoiesis, and in
 CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
 CC immune suppression and/or stimulation, as anti-inflammatory agents, and
 CC in treatment of leukaemias. AA029510 AA033064 represent the amino acid
 XX sequences of novel human secreted proteins of the invention.
 SQ Sequence 52 AA;
 Query Match 85.5%; Score 47; DB 22; Length 52;
 Best Local Similarity 90.4%; Pred No. 0.40;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 ELMRLQDYEE 11
 Db 14 ELMRLQDYEE 24
 RESULT 10
 AA027444
 ID AAY27444 standard; peptide: 27 AA.
 XX
 AC AAY27444;
 XX
 DT 26-NOV-1999 (first entry)
 XX
 DI Antennapedia internalization sequence in tandem with ezrin fragment.
 XX
 KW Pharmaceutical, ezrin, mutant, tumor, antennapedia internalization;
 KW metastasis; human.
 XX
 OS Synthetic.
 XX
 PH KEY Location/Qualifiers
 FT Modified-site 1 /note= "biotinylated"
 FT Modified site 22 /note= "optionally phosphorylated"
 XX
 PN W09947150-A2.
 XX
 PD 23-SEP-1999.
 XX
 PF 18-MAR-1999; 99WO-EP02054.
 XX
 PR 18-MAR-1998; 98US-0040725.
 XX
 PA (CURI-) INST CURIE.
 PA (CRES) CRES CENT NAT RECH SCI.
 XX
 PI Arpin M, Crepaldi T, Gautreau A, Louvard D;
 XX
 DR WPI: 1999-561851/47.
 XX
 PT New composition for prevention and treatment of tumors and metastasis
 PT
 PS Example 5; Page 14; 31pp; English.
 XX
 CC The invention provides a pharmaceutical composition containing ezrin
 CC protein, RNA or DNA mutated on tyrosine 353, or a functional fragment
 CC or derivative of the ezrin mutant. The new composition is useful for
 CC prevention and/or treatment of tumors, and especially metastasis. The
 CC present sequence represents an antennapedia internalization sequence in
 CC tandem with an ezrin fragment (residues 348-358). This is used in
 CC experiments of p85 interaction with phosphorylated ezrin peptides.
 XX
 SQ Sequence 27 AA;
 Query Match 74.5%; Score 41; DB 20; Length 27;

Best Local Similarity 100.0%; Pred. No. 2.7;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 ELMLRLQDYE 11
IIIIII IIII
DB 17 LRLQDYE 24

RESULT 11
ABG29165
ID ABG29165 standard; Protein: 44 AA.

XX AC ABG29165;
XX 13-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #29156.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
XX RW food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN W0200175067-A2.

XX PD 11-OCT-2001.

XX PF 30-MAR-2001; 2001W0-0500631.

XX PR 31-MAR-2000; 2000US-0540317.

XX PP 23-APR-2000; 2000US-0640167.

XX PA (HYSE) HYSEQ INC.

XX PI Drmanac RT, Liu C, Tang YL;

XX DR WPI; 2001-649362/73.

XX DB N-PSDB; AAS94352.

XX PT New isolated polynucleotide and encoded polypeptides, useful in
diagnostics, forensics, gene mapping, identification of mutations
responsible for genetic disorders or other traits and to assess
biodiversity.

XX PS Claim 20; SEQ ID NO 59524; 101pp; English.

XX CC The invention relates to isolated polynucleotide (I) and
polypeptide (II) sequences. (I) is useful as hybridisation probes,
polymerase chain reaction (PCR) primers, oligomers, and for chromosome
and gene mapping, and in recombinant production of (II). The
polynucleotides are also used in diagnostics as expressed sequence tags
for identifying expressed genes. (I) is useful in gene therapy techniques
to restore normal activity of (II) or to treat disease states involving
(II). (II) is useful for generating antibodies against it, detecting or
quantifying a polypeptide in tissue, as molecular weight markers and as
a food supplement. (II) and its binding partners are useful in medical
imaging of sites expressing (II). (I) and (II) are useful for treating
disorders involving aberrant protein expression or biological activity.
The polypeptide and polynucleotide sequences have applications in
diagnostics, forensics, gene mapping, identification of mutations
responsible for genetic disorders or other traits to assess biodiversity
and to produce other types of data and products dependent on DNA and
amino acid sequences. AAG00010-ABG20377 represent novel human
diagnostic amino acid sequences of the invention.
Note: The sequence data for this patent did not appear in the printed
specification, but was obtained in electronic format directly from WIPO
at http://wipo.int/pub/published_pct_sequences.

XX SQ Sequence 44 AA;

Query Match 72.7%; Score 49; DB 22; Length 344;
Best Local Similarity 80.0%; Pred. No. 53;
Matches 8; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMLRLQDYE 10
IIIIII IIII
DB 279 ELMLRLQDYE 288

RESULT 12

ABB39680
ID ABB39680 standard; Peptide: 57 AA.

XX AC ABB39680;

XX DT 04-FEB-2002 (first entry)

XX DE Peptide #7186 encoded by human foetal liver single exon probe.

XX KW Human; foetal liver; gene expression; single exon nucleic acid probe.

XX OS Homo sapiens.

XX PN W0200157277-A2.

XX PD 09-AUG-2001.

XX PF 30-JAN-2001; 2001W0-0500669.

XX PR 04-FEB-2000; 2000US-0180312.

XX PR 26-MAY-2000; 2000US-0207456.

XX PR 30-JUN-2000; 2000US-0608408.

XX PR 03-AUG-2000; 2000US-0632366.

XX PR 21-SEP-2000; 2000US-0234687.

XX PP 27-SEP-2000; 2000US-0236359.

XX PR 04-OCT-2000; 2000US-0024263.

XX PA (MOLE-) MOLECULAR DYNAMICS INC.

XX PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX DR WPI; 2001-483447/52.

XX PT Human genome-derived single exon nucleic acid probes useful for
analyzing gene expression in human foetal liver.

XX PS Claim 27; SEQ ID NO 32315; 639pp + sequence listing; English.

XX CC The invention relates to a single exon nucleic acid probe for
measuring human gene expression in a sample derived from human foetal
liver. The single exon nucleic acid probes may be used for predicting,
measuring and displaying gene expression in samples derived from human
foetal liver. The present sequence is a peptide encoded by a single exon
nucleic acid probe of the invention.
Note: The sequence data for this patent did not form part of the
printed specification, but was obtained in electronic format directly
from WIPO at http://wipo.int/pub/published_pct_sequences.

XX SQ Sequence 57 AA;

Query Match 70.9%; Score 39; DB 22; Length 57;
Best Local Similarity 72.7%; Pred. No. 14;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMLRLQDYE 11
IIIIII IIII
DB 18 ELMLRLQDYE 28

RESULT 13

AAM60396
ID AAM60396 standard; Protein: 57 AA.

XX AC AAM60396;

XX DT 05-NOV-2001 (first entry)

Pl Human genome derived single exon nucleic acid probes useful for
 Pt analyzing gene expression in human placenta -
 XX
 PS Claim 27: SEQ ID No 33525: 654bp; English.
 XX
 Cc The present invention relates to single exon nucleic acid probes (SENPs;
 Cc see AA131315-AA157546). The present sequence is a peptide encoded by one
 Cc such probe. The probes are useful for producing a microarray for
 Cc prediction, measuring and displaying gene expression in samples derived
 Cc from human placenta. The probes are useful for antenatal diagnosis of
 Cc human genetic disorders.

XX Sequence 57 AA:

Query Match 70.9%; Score 49; DB 22; Length 57;
 Best Local Similarity 72.7%; Pred. No. 13;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMLRLQDYER 11
 DB 18 ELMLRLQDYER 28

Search completed: January 16, 2003, 16:49:15
 Job time : 52.3286 secs